(lp0
S'MEI Pharma to Present at Needham Healthcare Conference Yahoo Finance - 17 hours ago SAN DIEGO, March 28, 2017 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.In focus: MEI Pharma, Inc.  Trading Patterns - Post Analyst'
p1
aS"MEI Pharma Inc  Poised To Move Higher; Here's Why Smarter Analyst - Apr 19, 2016 Having seen the updated Pracinostat overall survival data in elderly Acute Myeloid Leukemia  from MEI Pharma  presented at the recent Needham Healthcare Conference, I believe this is another opportunity to buy a severely&nbsp;..."
p2
aS'MEI Pharma: Upcoming Catalysts Will Drive Stock Rebound Seeking Alpha  - Mar 24, 2015 The ~80% gain in MEI Pharma  in less than 2 months since my article was too much for me to pass up completely as I hedged my bet.MEI Pharma Announces Top-Line Data From Randomized Phase II Clinical Study Of ... - PR Newswire Can MEI Pharma Survive? - 24/7 Wall St.'
p3
aS"MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A ... PR Newswire  - Apr 20, 2016 SAN DIEGO, April 20, 2016 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, announced new clinical data from a first-in-human study of MEI Pharma's investigational&nbsp;..."
p4
aS'MEI Pharma Should Be Bought Ahead Of ASH Conference Seeking Alpha - Nov 4, 2015 Pracinostat Phase 2 data presented at ASH will illustrate survival benefit in AML and favorable outcomes in MDS patients. MEI Pharma also has two other promising clinical stage drugs in the pipeline with PWT143,  and a novel&nbsp;...'
p5
aS'Wedbush Top Analyst Remains Sidelined on MEI Pharma Inc  Despite ... Smarter Analyst - Aug 3, 2016 MEI Pharma Inc  just received Breakthrough Therapy Designation for its key pipeline drug pracinostat, anti-tumor molecule inhibitor that combined with azacitidine treats patients with newly diagnosed acute myeloid leukemia  who are&nbsp;...'
p6
aS'MEI Pharma Undervalued As Pracinostat Advances To Phase 3 In AML Seeking Alpha - Dec 30, 2015 By all metrics, updated data presented at ASH detailing the efficacy of Pracinostat combo in elderly AML was impressive. Median OS of 14+ months and counting.'
p7
aS'MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in ... PR Newswire  - Dec 7, 2015 SAN DIEGO, Dec. 7, 2015 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate&nbsp;...'
p8
aS"Some Ideas For The Next Celator Seeking Alpha - Jun 2, 2016 Celator Pharmaceuticals is being acquired by Jazz Pharmaceuticals capping a more than 1500% rise in Celator's share price in just a few months."
p9
aS"What MEI Pharma Inc 's $444 Million Deal Really Means Scibility Media - Aug 9, 2016 MEI Pharma Inc. 's efforts to develop its pipeline product pracinostat to treat acute myeloid leukemia  recently received a major boost in the form of a partnership with Swiss drug company Helsinn Group.MEI Pharma Partners with Helsinn on Drug with Potential $464M Payoff - Xconomy"
p10
a.